Recursion Pharmaceuticals Ownership | Who Owns Recursion Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Recursion Pharmaceuticals Ownership Summary


Recursion Pharmaceuticals is owned by 92.31% institutional investors, 4.52% insiders, and 3.16% retail investors. Ark investment management is the largest institutional shareholder, holding 11.92% of RXRX shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 6.32% of its assets in Recursion Pharmaceuticals shares.

RXRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockRecursion Pharmaceuticals92.31%4.52%3.16%
SectorHealthcare Stocks 88.01%8.90%3.09%
IndustryBiotech Stocks 109.70%8.77%-18.47%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management28.14M11.92%$211.07M
Baillie gifford26.59M11.27%$199.42M
Vanguard group21.56M9.13%$161.67M
Blackrock17.31M7.33%$129.83M
Ra capital management15.38M6.52%$115.38M
Mubadala investment co pjsc12.99M5.50%$97.39M
Kinnevik ab (publ)11.91M4.21%$80.48M
Nikko asset management americas9.93M4.21%$74.31M
State street8.75M3.71%$65.62M
Mic capital management uk llp8.45M3.58%$63.39M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kinnevik ab (publ)11.91M100.00%$80.48M
Dcvc opportunity fund ii gp3.95M44.95%$29.63M
Data collective iv gp5.94M31.23%$44.56M
Nvidia7.71M14.70%$57.80M
Mic capital management uk llp8.45M13.78%$63.39M
Ark investment management28.14M1.87%$211.07M
Ra capital management15.38M1.53%$115.38M
Exor capital llp3.68M0.93%$27.56M
Nikko asset management americas9.93M0.86%$74.31M
Commons capital108.52K0.66%$733.60K

Top Buyers

HolderShares% AssetsChange
Ra capital management15.38M1.53%15.38M
Vanguard group21.56M0.00%5.54M
Blackrock17.31M0.00%4.99M
Ark investment management28.14M1.87%3.56M
Baillie gifford26.59M0.16%2.52M

Top Sellers

HolderShares% AssetsChange
Laurion capital management lp---2.90M
State street8.75M0.00%-1.60M
Platinum investment management395.67K0.12%-1.40M
Ghisallo capital management---1.10M
Fmr8.19M0.00%-1.07M

New Positions

HolderShares% AssetsChangeValue
Ra capital management15.38M1.53%15.38M$115.38M
Norges bank1.95M0.00%1.95M$14.60M
Woodline partners lp664.45K0.05%664.45K$4.98M
Neuberger berman group355.64K0.00%355.64K$2.67M
Scientech research140.29K0.22%140.29K$1.05M

Sold Out

HolderChange
Financial gravity asset management-4.00
Householder group estate & retirement specialist-11.00
Gradient investments-15.00
Corecap advisors-26.00
Nelson, van denburg & campbell wealth management group-28.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2024275-1.43%260,863,9783.59%920.81%154-13.97%49-
Jun 30, 20242778.20%251,804,69520.07%1061.35%17712.74%49-5.77%
Mar 31, 202425625.49%209,712,7241.55%881.13%15738.94%5215.56%
Dec 31, 20232042.00%206,519,35235.69%881.76%113-14.39%4525.00%
Sep 30, 202320025.79%152,197,13419.37%711.77%13257.14%36-14.29%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite17.83M6.32%1.17M
ARK Innovation ETF18.37M4.70%-324.48K
Scottish Mortgage Ord18.17M4.65%-
ARK Genomic Revolution12.71M4.50%3.20M
Vanguard Total Stock Mkt Idx Inv11.59M2.97%3.92M
ARK Genomic Revolution ETF11.57M2.96%-475.38K
Vanguard Small Cap Index9.23M2.36%2.98M
SPDR® S&P Biotech ETF6.78M1.74%-79.27K
iShares Russell 2000 ETF6.71M1.72%-25.75K
Vanguard Small Cap Growth Index Inv5.25M1.34%1.80M

Recent Insider Transactions


DateNameRoleActivityValue
Jan 10, 2025Gibson Christopher Chief Executive OfficerSell$141.00K
Jan 08, 2025Gibson Christopher Chief Executive OfficerSell$146.20K
Dec 04, 2024Gibson Christopher Chief Executive OfficerSell$143.20K
Dec 05, 2024Gibson Christopher Chief Executive OfficerSell$142.40K
Nov 13, 2024Gibson Christopher Chief Executive OfficerSell$154.80K

Insider Transactions Trends


DateBuySell
2024 Q4-15
2024 Q3-21
2024 Q2-22
2024 Q1-33
2023 Q4-27

RXRX Ownership FAQ


Who Owns Recursion Pharmaceuticals?

Recursion Pharmaceuticals shareholders are primarily institutional investors at 92.31%, followed by 4.52% insiders and 3.17% retail investors. The average institutional ownership in Recursion Pharmaceuticals's industry, Biotech Stocks , is 109.70%, which Recursion Pharmaceuticals falls below.

Who owns the most shares of Recursion Pharmaceuticals?

Recursion Pharmaceuticals’s largest shareholders are Ark investment management (28.14M shares, 11.92%), Baillie gifford (26.59M shares, 11.27%), and Vanguard group (21.56M shares, 9.13%). Together, they hold 32.32% of Recursion Pharmaceuticals’s total shares outstanding.

Does Blackrock own Recursion Pharmaceuticals?

Yes, BlackRock owns 7.33% of Recursion Pharmaceuticals, totaling 17.31M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 129.83M$. In the last quarter, BlackRock increased its holdings by 4.99M shares, a 40.49% change.

Who is Recursion Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Kinnevik ab (publ) is Recursion Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 100.00% of its assets in 11.91M Recursion Pharmaceuticals shares, valued at 80.48M$.

Who is the top mutual fund holder of Recursion Pharmaceuticals shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Recursion Pharmaceuticals shares, with 6.32% of its total shares outstanding invested in 17.83M Recursion Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools